PLUR Stock Overview
A biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.05 |
| 52 Week High | US$8.48 |
| 52 Week Low | US$3.77 |
| Beta | 1.63 |
| 11 Month Change | 6.32% |
| 3 Month Change | -0.50% |
| 1 Year Change | 1.81% |
| 33 Year Change | -76.00% |
| 5 Year Change | -81.81% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
Pluri gains as PROTO project receives €7.5M EU grant
Sep 06Pluristem Therapeutics renames as Pluri
Jul 25Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?
Dec 04
We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully
Aug 18What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
Mar 15We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely
Feb 08
Pluristem Therapeutics launches $30M registered direct offering
Feb 02Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?
Jan 04Pluristem expands COVID-19 program in Mexico
Dec 29Pluristem - Moment Of Truth
Dec 08Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Nov 30Shareholder Returns
| PLUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.4% | -7.5% | -1.2% |
| 1Y | 1.8% | 14.1% | 30.4% |
Return vs Industry: PLUR underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: PLUR underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| PLUR volatility | |
|---|---|
| PLUR Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PLUR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PLUR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 112 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform. The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
Pluri Inc. Fundamentals Summary
| PLUR fundamental statistics | |
|---|---|
| Market cap | US$27.85m |
| Earnings (TTM) | -US$21.81m |
| Revenue (TTM) | US$598.00k |
46.9x
P/S Ratio-1.3x
P/E RatioIs PLUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUR income statement (TTM) | |
|---|---|
| Revenue | US$598.00k |
| Cost of Revenue | US$130.00k |
| Gross Profit | US$468.00k |
| Other Expenses | US$22.28m |
| Earnings | -US$21.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.92 |
| Gross Margin | 78.26% |
| Net Profit Margin | -3,646.99% |
| Debt/Equity Ratio | -40,261.9% |
How did PLUR perform over the long term?
See historical performance and comparison